Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarsveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 May 25. pii: S1083-8791(19)30332-5. doi: 10.1016/j.bbmt.2019.05.021. [Epub ahead of print]

PMID:
31136799
2.

Aspirin and Chemoprevention-Have We Arrived?

Seewaldt VL.

JAMA Oncol. 2018 Dec 1;4(12):1668-1669. doi: 10.1001/jamaoncol.2018.4138. No abstract available.

PMID:
30286216
3.

Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.

Dietze EC, Chavez TA, Seewaldt VL.

Am J Pathol. 2018 Feb;188(2):280-290. doi: 10.1016/j.ajpath.2017.09.018. Epub 2017 Nov 9. Review.

4.

Multiplexed Detection of MicroRNA Biomarkers Using SERS-Based Inverse Molecular Sentinel (iMS) Nanoprobes.

Wang HN, Crawford BM, Fales AM, Bowie ML, Seewaldt VL, Vo-Dinh T.

J Phys Chem C Nanomater Interfaces. 2016 Sep 22;120(37):21047-21050. doi: 10.1021/acs.jpcc.6b03299. Epub 2016 Jul 1.

5.

Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.

Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D.

Cancer Prev Res (Phila). 2017 Nov;10(11):641-650. doi: 10.1158/1940-6207.CAPR-17-0106. Epub 2017 Sep 6.

6.

Förster resonance energy transfer to impart signal-on and -off capabilities in a single microRNA biosensor.

Larkey NE, Zhang L, Lansing SS, Tran V, Seewaldt VL, Burrows SM.

Analyst. 2016 Oct 24;141(22):6239-6250.

PMID:
27704084
7.

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, Richards-Kortum R, Jia W, Seewaldt VL, Yu D.

Cancer Res. 2015 Nov 15;75(22):4863-75. doi: 10.1158/0008-5472.CAN-14-2345. Epub 2015 Sep 17.

8.

WWOX loss activates aerobic glycolysis.

Abu-Remaileh M, Seewaldt VL, Aqeilan RI.

Mol Cell Oncol. 2014 Oct 30;2(2):e965640. doi: 10.4161/23723548.2014.965640. eCollection 2015 Apr-Jun.

9.

Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death.

Girard BJ, Regan Anderson TM, Welch SL, Nicely J, Seewaldt VL, Ostrander JH.

PLoS One. 2015 Mar 19;10(3):e0121206. doi: 10.1371/journal.pone.0121206. eCollection 2015.

10.

Triple-negative breast cancer in African-American women: disparities versus biology.

Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL.

Nat Rev Cancer. 2015 Apr;15(4):248-54. doi: 10.1038/nrc3896. Epub 2015 Feb 12. Review.

11.

Tumor mechanics and metabolic dysfunction.

Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, Eliceiri KW, Keely PJ, Seewaldt VL, Weaver VM.

Free Radic Biol Med. 2015 Feb;79:269-80. doi: 10.1016/j.freeradbiomed.2014.11.020. Epub 2014 Dec 19. Review.

12.

Model of tumor dormancy/recurrence after short-term chemotherapy.

Li S, Kennedy M, Payne S, Kennedy K, Seewaldt VL, Pizzo SV, Bachelder RE.

PLoS One. 2014 May 20;9(5):e98021. doi: 10.1371/journal.pone.0098021. eCollection 2014.

13.

Cancer: Destiny from density.

Seewaldt VL.

Nature. 2012 Oct 25;490(7421):490-1. doi: 10.1038/490490a. No abstract available.

14.

Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.

D'Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD, Bell K, Young LJ, Simin K, Bachelder RE, Delrow J, Dawson A, Yee LD, Mrózek K, Clay TM, Osada T, Seewaldt VL.

PLoS One. 2012;7(9):e45684. doi: 10.1371/journal.pone.0045684. Epub 2012 Sep 25.

15.

Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?

Ibarra-Drendall C, Dietze EC, Seewaldt VL.

Curr Breast Cancer Rep. 2011 Sep;3(3):142-150. Epub 2011 Jul 13.

16.

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfkuhle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL.

Breast Cancer Res Treat. 2012 Apr;132(2):487-98. doi: 10.1007/s10549-011-1609-9. Epub 2011 Jun 7. Erratum in: Breast Cancer Res Treat. 2012 Oct;135(3):925.

17.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82. doi: 10.1158/1055-9965.EPI-10-0847. Epub 2011 Jan 17.

18.

Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.

Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK.

Breast Cancer Res Treat. 2011 Jul;128(2):483-93. doi: 10.1007/s10549-011-1347-z. Epub 2011 Jan 12.

PMID:
21225455
19.

Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.

Ostrander JH, McMahon CM, Lem S, Millon SR, Brown JQ, Seewaldt VL, Ramanujam N.

Cancer Res. 2010 Jun 1;70(11):4759-66. doi: 10.1158/0008-5472.CAN-09-2572. Epub 2010 May 11.

20.

Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines.

Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N.

Breast Cancer Res Treat. 2011 Feb;126(1):55-62. doi: 10.1007/s10549-010-0884-1.

PMID:
20390344
21.

Comments and response on the USPSTF recommendation on screening for breast cancer.

Seewaldt VL.

Ann Intern Med. 2010 Apr 20;152(8):541-2; author reply 543-4. doi: 10.7326/0003-4819-152-8-201004200-00205. Epub 2010 Feb 15. No abstract available.

PMID:
20157105
22.

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D.

Cancer Cell. 2009 Sep 8;16(3):195-207. doi: 10.1016/j.ccr.2009.08.010.

23.

Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study.

Ibarra-Drendall C, Wilke LG, Zalles C, Scott V, Archer LE, Lem S, Yee LD, Lester J, Kulkarni S, Murekeyisoni C, Wood M, Wilson K, Garber J, Gentry C, Stouder A, Broadwater G, Baker JC Jr, Vasilatos SN, Owens E, Rabiner S, Barron AC, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1379-85. doi: 10.1158/1055-9965.EPI-08-1210. Epub 2009 Apr 21.

24.

CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.

25.

Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial.

Carson JW, Carson KM, Porter LS, Keefe FJ, Seewaldt VL.

Support Care Cancer. 2009 Oct;17(10):1301-9. doi: 10.1007/s00520-009-0587-5. Epub 2009 Feb 12.

PMID:
19214594
26.

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.

27.

Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.

Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41.

28.

Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.

29.

Images in clinical medicine. Rapid progression of basal-type breast cancer.

Seewaldt VL, Scott V.

N Engl J Med. 2007 Mar 29;356(13):e12. No abstract available.

30.

Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology.

Seewaldt VL, Goldenberg V, Jones LW, Peace C, Broadwater G, Scott V, Bean GR, Wilke LG, Zalles CM, Demark-Wahnefried W.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):613-6.

31.

Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.

De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, Coussens LM, Cohen MB.

Cancer Biol Ther. 2006 Dec;5(12):1588-99. Epub 2006 Dec 6. No abstract available.

PMID:
17224636
32.

Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6.

33.

Long-term raloxifene in a woman at high risk for breast cancer.

Bean GR, Kimler BF, Seewaldt VL.

N Engl J Med. 2006 Oct 12;355(15):1620-2. No abstract available.

PMID:
17035661
34.

Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells.

Bowie ML, Troch MM, Delrow J, Dietze EC, Bean GR, Ibarra C, Pandiyan G, Seewaldt VL.

Oncogene. 2007 Mar 29;26(14):2017-26. Epub 2006 Oct 2.

PMID:
17016442
35.

The gift of being first-generation American.

Seewaldt VL.

Cancer Biol Ther. 2006 Aug;5(8):1042-5. Epub 2006 Aug 26. No abstract available.

PMID:
16931904
36.

CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5.

Dietze EC, Bowie ML, Mrózek K, Caldwell LE, Neal C, Marjoram RJ, Troch MM, Bean GR, Yokoyama KK, Ibarra CA, Seewaldt VL.

J Cell Sci. 2005 Nov 1;118(Pt 21):5005-22. Epub 2005 Oct 11.

37.

Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.

Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, Marcom PK, Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Wilke LG, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8.

38.

Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy.

Shaw HS, Hobbs KB, Kroll DJ, Seewaldt VL.

J Clin Oncol. 2004 Nov 1;22(21):4432-4. No abstract available. Erratum in: J Clin Oncol. 2005 Feb 20;23(6):1337.

PMID:
15514390
39.

Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells.

Bowie ML, Dietze EC, Delrow J, Bean GR, Troch MM, Marjoram RJ, Seewaldt VL.

Oncogene. 2004 Nov 18;23(54):8743-55.

PMID:
15467738
40.

Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL.

J Natl Cancer Inst. 2004 Jun 2;96(11):883; author reply 884-5. No abstract available.

PMID:
15173275
41.

Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity.

Dietze EC, Troch MM, Bean GR, Heffner JB, Bowie ML, Rosenberg P, Ratliff B, Seewaldt VL.

Oncogene. 2004 May 6;23(21):3851-62.

PMID:
14990993
42.

The antiproliferative effects of PPARgamma ligands in normal human mammary epithelial cells.

Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK, Seewaldt VL.

Breast Cancer Res Treat. 2003 Mar;78(2):179-92.

PMID:
12725418
43.

CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.

Dietze EC, Troch MM, Bowie ML, Yee L, Bean GR, Seewaldt VL.

Biochem Biophys Res Commun. 2003 Mar 21;302(4):841-8.

PMID:
12646247
44.

Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.

Dietze EC, Caldwell LE, Marcom K, Collins SJ, Yee L, Swisshelm K, Hobbs KB, Bean GR, Seewaldt VL.

Microsc Res Tech. 2002 Oct 1;59(1):23-40.

PMID:
12242694
45.

Retinoic acid receptor beta2 inhibition of metastasis in mouse mammary gland xenografts.

Treuting PM, Chen LI, Buetow BS, Zeng W, Birkebak TA, Seewaldt VL, Sommer KM, Emond M, Maggio-Price L, Swisshelm K.

Breast Cancer Res Treat. 2002 Mar;72(1):79-88.

PMID:
12000222
46.

Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis.

Seewaldt VL, Mrózek K, Sigle R, Dietze EC, Heine K, Hockenbery DM, Hobbs KB, Caldwell LE.

J Cell Biol. 2001 Oct 29;155(3):471-86. Epub 2001 Oct 22.

48.

Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis.

Seewaldt VL, Mrózek K, Dietze EC, Parker M, Caldwell LE.

Cancer Res. 2001 Jan 15;61(2):616-24.

49.

Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization.

Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL.

J Biol Chem. 2001 Feb 16;276(7):5384-94. Epub 2000 Nov 27.

50.

Dysregulated expression of cyclin D1 in normal human mammary epithelial cells inhibits all-trans-retinoic acid-mediated G0/G1-phase arrest and differentiation in vitro.

Seewaldt VL, Kim JH, Parker MB, Dietze EC, Srinivasan KV, Caldwell LE.

Exp Cell Res. 1999 May 25;249(1):70-85.

PMID:
10328955

Supplemental Content

Loading ...
Support Center